GlassScriptPhysician profile
Maqsood Amjad
NPI 1881631398
$8,703.73
in general payments reported to CMS, 2019-2025
39 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $1,236 · 2021: $43.12 · 2022: $309 · 2023: $6,458 · 2024: $333 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,550 · Food and Beverage: $1,532 · Travel and Lodging: $715 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,550.00 |
| Food and Beverage | $1,532.31 |
| Travel and Lodging | $714.50 |
| Education | $216.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $5,656.84 | 2023 | |
| Celgene Corporation | $1,189.18 | 2020-2023 | Reblozyl |
| Daiichi Sankyo INC. | $154.30 | 2022-2024 | Enhertu |
| Karyopharm Therapeutics INC. | $150.01 | 2020-2023 | Xpovio |
| Exelixis INC. | $147.07 | 2022-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $141.48 | 2020-2025 | Opdivo |
| Incyte Corporation | $113.69 | 2023-2025 | Jakafi |
| Blueprint Medicines Corporation | $113.38 | 2023 | Ayvakit |
| Seagen INC. | $99.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $77.48 | 2019-2024 | |
| Astellas Pharma US INC | $75.89 | 2019-2024 | Xtandi, Xospata |
| Regeneron Healthcare Solutions, INC. | $68.06 | 2024 | Libtayo |
| Pfizer INC. | $59.91 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $58.66 | 2019-2020 | |
| Abbvie INC. | $54.02 | 2023-2025 | Venclexta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.02 | 2023-2024 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $39.26 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $35.85 | 2019-2024 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $35.73 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Eisai INC. | $35.32 | 2023-2024 | |
| Emmaus Medical, INC. | $28.69 | 2022 | |
| Aveo Pharmaceuticals, INC. | $26.04 | 2025 | |
| Amgen INC. | $23.95 | 2023 | Lumakras |
| Dendreon Pharmaceuticals LLC | $22.31 | 2024 | Provenge |
| Adc Therapeutics America, INC. | $21.19 | 2023 | |
| Mirati Therapeutics, INC. | $20.47 | 2024 | Krazati |
| Spectrum Pharmaceuticals INC. | $19.88 | 2023 | Rolvedon |
| Myriad Genetic Laboratories, INC. | $18.91 | 2025 | Myrisk |
| Genentech USA, INC. | $18.41 | 2025 | Venclexta |
| Pharmaessentia USA Corporation | $18.27 | 2025 | Besremi |
| Array Biopharma INC | $18.23 | 2025 | Mektovi, Lorbrena, Braftovi |
| Telix Pharmaceuticals | $17.91 | 2025 | Illuccix |
| Agios Pharmaceuticals, INC. | $16.55 | 2023 | Pyrukynd |
| Sumitomo Pharma America, INC. | $16.12 | 2023 | Orgovyx |
| Genzyme Corporation | $14.99 | 2020 | |
| Sobi, INC | $14.24 | 2024 | |
| Lilly USA, LLC | $13.87 | 2019 | |
| Beigene USA, INC. | $13.56 | 2024 | Brukinsa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maqsood Amjad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.